and Numinus' leadership in psychedelic-assisted psychotherapy in Canada creates a best-in-class company. The combination of Novamind's network of mental health clinics and research sites in the U.S. Yaron Conforti, CEO and co-founder, Novamind, stated, "This transaction offers significant value for Novamind's shareholders and provides compelling new opportunities for our employees, patients and research partners. We look forward to welcoming the Novamind team to the Numinus family." Our combined capabilities will deliver exceptional value for our clients, employees, and shareholders. Nyquvest continued: "We expect this acquisition will significantly bolster our financial performance, growing Numinus' annual revenue to more than five times our current levels, and driving meaningful margin improvement through identified operating efficiencies. market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness." "We prioritize working with the best partners in this industry and Novamind's U.S. platform through eight established, reputable, efficiently operating and revenue-producing clinics," stated Payton Nyquvest, founder and CEO, Numinus. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. "Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine.
0 Comments
Leave a Reply. |